LAS VEGAS--(BUSINESS WIRE)--CardioVascular BioTherapeutics, Inc. (OTCBB: CVBT) has engaged The Bruckner Group (BGI) to assist CVBT in finding a joint commercialization partner for its drug candidate CVBT-141H to treat severe coronary heart disease (CHD). The drug contains the active pharmaceutical ingredient (API) human fibroblast growth factor -1 (FGF-1).
